Monoclonal antibody treatment for multiple sclerosis and neuromyelitis optica spectrum disorder: An update

Abstract

Anti-mAbs treatments have revolutionized the treatment of MS and NMOSD. Over the last few years, there has been remarkable progress in the treatment of multiple sclerosis (MS) and optic neuromyelitis optica spectrum disorder (NMOSD), especially with the approval of new and advanced treatment options such as multiple antimonoclonal antibodies (mAbs). This poses several questions, such as whether B-cell-depleting options such as rituximab increases the risk of COVID-19 or its severity, if COVID-19 vaccine is effective, and when to initiate anti-mAb treatment. [Extracted from the article] Copyright of Clinical & Experimental Neuroimmunology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)